10 news items
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
NKGN
3 Jun 24
such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those
Spotlighting Unexplored Stocks in Focus: NKGN, INBS, BTBT, PRSO, MGOL
BTBT
INBS
MGOL
24 May 24
earnings surprise. CEO and CFO will present at a virtual conference on May 30, offering investors access to webcast materials on the company's site
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
NKGN
23 May 24
therapies from materials collected from a single donor. Thus, our potential to treat a significant number of cancer patients with SNK02 is remarkably high
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease
NKGN
20 May 24
are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed
NKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & Exhibition
NKGN
16 May 24
such statements are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those
v9ue57 mn0csl
NKGN
25 Apr 24
control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include
yzdqxi5zt
NKGN
24 Apr 24
of the Company's control, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements
vycp 5zvyp
NKGN
11 Apr 24
are subject to risks and uncertainties, many of which are outside of the Company's control, actual results may differ materially from those expressed
mrdh14
NKGN
25 Mar 24
/duration was initiated in the U.S. in 2023.A copy of the abstract and presentation materials will be available on the Scientific
yrp 7xxcvo2
NKGN
25 Mar 24
. in 2023. A copy of the abstract and presentation materials will be available on the Scientific Publications page
- Prev
- 1
- Next